Does chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta1 mRNA ameliorate renal injury in hypertensive rats?
These results suggest that chimeric DNA-RNA ribozyme to TGF-beta1 may be useful as a gene therapy for progressive tissue injury in a wide variety of renal diseases, including hypertensive nephrosclerosis.
The positive effects of fetal liver cell and cell-free fetal-specific factors in experimental cirrhosis may result from the presence of stage-specific factors activating hepatocellular repair.